Videos

Concluding his reflection on novel therapies in patients with cholangiocarcinoma, Milind Javle, MD, provides closing thoughts and practical advice for his community colleagues.

Dr Milind Javle discusses novel therapies recently approved or under investigation across multiple lines of therapy in patients with cholangiocarcinoma.

Milind Javle, MD, shares his personal experience and insights on the approval and use of infigratinib, an FGFR2 fusion–targeted therapy, in patients with previously treated advanced cholangiocarcinoma.

Oncologist Dr. Milind Javel provides an overview of first- and subsequent-line treatments for patients with cholangiocarcinoma.

Dr Milind Javle discusses challenges that exist in the early identification of cholangiocarcinoma, as well as the benefits of comprehensive molecular profiling.

Expert oncologist Milind Javle, MD, reviews the diagnosis and treatment of intrahepatic cholangiocarcinoma in a 61-year-old who presents with jaundice and changes in stool and urine color.

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

Implications for treating unfit patients with relapsed/refractory diffuse large B-cell lymphoma with chemotherapy or the combination of tafasitamab and lenalidomide based on patient characteristics and the L-MIND trial.

Recommendations for approaching patients with relapsed/refractory diffuse large B-cell lymphoma with newer targeted treatment approaches as frontline therapy vs referral for transplant.

Ronald S. Go, MD, a hematology oncologist with the Mayo Clinic, discusses treating and diagnosing histiocytic neoplasms, a rare hematologic cancer.

The rationale for sequencing therapy with CD19-targeted agents when managing patients with various subtypes of diffuse large B-cell lymphoma.

Variables that impact a patient with diffuse large B-cell lymphoma, and prognosis and strategies for counseling patients on goals of therapy.

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.

Thomas Powles, MD, MBBS, MRCP, discusses the results of the phase 3 EV-301 trial for enfortumab vedotin in patients with urothelial cancer.

Matthew R. Smith, MD, PhD, discusses areas of unmet needs and clinical pearls for the management of patients with mCRPC.

Prostate cancer expert Dr Smith elaborates on treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on systemic therapy.

Matthew R. Smith, MD, PhD, shares his personal experience using darolutamide for patients with prostate cancer.

Dr Matthew Smith discusses next generation androgen receptor inhibitors and data from clinical trials with these agents.

Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).

Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.

Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.

The expert panel discusses trials underway in the adjuvant setting and the role of adjuvant therapy in patients with RCC.

Bradley McGregor, MD, reviews data from the Keynote-564 study on the use of immunotherapy in the adjuvant setting.

The expert panel discusses the role of multidisciplinary teams in treatment of patients with RCC.

Bradley McGregor, MD, reviews the case of a 62-year-old man with mRCC and the use of adjuvant therapy for RCC.

Dr Eric Jonasch and the panel discuss TIVO-3 trial data and use of tivozanib and HIF3α inhibitors in mRCC.

RCC experts discuss dose modifications and management of adverse events in patients with favorable-risk mRCC.

Eric Jonasch, MD, and the panel discuss NCCN Guidelines’ preferred second-line treatment options in mRCC.

The expert panel and Dr Eric Jonasch discuss data on first-line immunochemotherapy combinations for favorable-risk mRCC.